{"id":2153,"date":"2020-06-09T19:12:27","date_gmt":"2020-06-09T19:12:27","guid":{"rendered":"https:\/\/www.saintjohnscancer.org\/blog\/?p=2153"},"modified":"2026-06-03T19:31:35","modified_gmt":"2026-06-03T19:31:35","slug":"making-advancements-in-cancer-treatments","status":"publish","type":"post","link":"https:\/\/www.saintjohnscancer.org\/blog\/research\/making-advancements-in-cancer-treatments\/","title":{"rendered":"Making Advancements in Cancer Treatments"},"content":{"rendered":"\n<p>The <strong>Translational Neurosciences<\/strong> department at the Saint John&rsquo;s Cancer Institute is committed to accelerate the development of novel therapies for brain cancers and neurological disorders through innovations in immunotherapy and precision medicine. Under the leadership of world-renowned neuroscientist and neuro-oncologist, <strong><a href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/santosh-kesari\/\">Dr. Santosh Kesari, M.D., Ph.D.,<\/a><\/strong> the department is focusing on leading-edge basic and translational research, innovative clinical trials, and comprehensive, personalized treatments to give cancer patients hope for a future.<\/p>\n<p>Dr. Kesari&rsquo;s driven <strong><a href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/neurosciences\/meet-our-team\/\">team<\/a><\/strong> of experts are developing and advancing life-changing treatments for patients with brain and skull based tumors and other&nbsp;<a href=\"https:\/\/www.saintjohnscancer.org\/neurosciences\/conditions\/\"><strong>neurological conditions<\/strong><\/a>.<\/p>\n<h3>Learn about our featured publications to advance cancer treatments:<\/h3>\n<ul>\n<li>Jeffrey J. Rodvold, Su Xian, Julia Nussbacher, Brian Tsui, T. Cameron Waller, Stephen C. Searles, Alyssa Lew, Pengfei Jiang, Ivan Babic, Natsuko Nomura, Jonathan H. Lin, <a href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/santosh-kesari\/\"><strong>Santosh<\/strong> <strong>Kesari<\/strong><\/a>, Hannah Carter &amp; Maurizio Zanetti, have published a new study in <strong><em>Scientific Report<\/em><\/strong>, entitled: <strong><em>IRE1&alpha; and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells<\/em><\/strong>. Glioblastoma is notoriously resistant to radiation and chemotherapy. In this publication, they used patient-derived GBM neurosphere lines to show that Insulin Growth Factor signaling (IGF-1) correlated with resistance to therapy. Further validation was done using weighted gene correlation network analysis, CRISPR technology, and analysis of The Cancer Genome Atlas (TCGA) that inhibiting IGF-1 pathway induced cell death. Read the publication to learn how his study highlights a common mechanism of tumor resistance and opportunity to target this in future studies to improve outcomes.<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><a class=\"btn btn--primary\" href=\"https:\/\/www.nature.com\/articles\/s41598-020-65320-6\" target=\"_blank\" rel=\"noopener noreferrer\">Learn More<\/a><\/strong><\/p>\n<ul>\n<li>Her NG,<strong>&nbsp;<a href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/santosh-kesari\/\">Kesari S<\/a><\/strong>, and <strong>Nurmemmedov E<\/strong>, have published a new study in <strong><em>Cell Cycle<\/em><\/strong>, entitled: <strong><em>Thrombospondin-1 Counteracts the p97 Inhibitor CB-5083 in Colon Carcinoma Cells. <\/em><\/strong>This publication demonstrates that Thrombospondin-1 (THBS1) is a CB-5083-upregulated gene that helps confer resistance of HCT116 cells to CB-5083. Learn how their data provides new evidence that THBS1 is important for the susceptibility of cells to p97 inhibition.<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><a class=\"btn btn--primary\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32423265\/?from_term=kesari+s&amp;from_sort=date&amp;from_size=50&amp;from_pos=2\" target=\"_blank\" rel=\"noopener noreferrer\">Learn More<\/a><\/strong><\/p>\n<ul>\n<li>Cheltsov A, Nomura N, Yenugonda VM, Roper J, Mukthavaram R, Jiang P, Her NG, Babic I, <a href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/santosh-kesari\/\"><strong>Kesari S<\/strong><\/a>, and <strong>Nurmemmedov E<\/strong>, have published a new study in <strong><em>Scientific Report<\/em><\/strong><strong>s<\/strong>, entitled:<strong><em> Allosteric inhibitor of &beta;-catenin selectively targets oncogenic Wnt signaling in colon cancer. <\/em><\/strong>This publication presents a novel pharmacologic approach for selective inhibition of &beta;-catenin via targeting a cryptic allosteric modulation site. Learn how their findings may provide a new perspective for therapeutic targeting of &beta;-catenin for many cancers.<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><a class=\"btn btn--primary\" href=\"https:\/\/www.nature.com\/articles\/s41598-020-60784-y\" target=\"_blank\" rel=\"noopener noreferrer\">Learn More<\/a><\/strong><\/p>\n<h4><\/h4>\n<h4 style=\"text-align: center;\">Visit our Translational Neurosciences department to view all of our novel research topics.<\/h4>\n<p style=\"text-align: center;\"><strong><a class=\"btn btn--primary\" href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/neurosciences\/current-research-topics\/\" rel=\"noopener noreferrer\">Research Topics<\/a><\/strong><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>The Translational Neurosciences department at the Saint John&rsquo;s Cancer Institute is committed to accelerate the development of novel therapies for&#8230;<\/p>\n","protected":false},"author":5,"featured_media":2154,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[150,174],"tags":[184],"class_list":["post-2153","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","category-brain-tumor","tag-brain-cancer"],"acf":{"doc_author":"0","header_scripts":""},"_links":{"self":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts\/2153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/comments?post=2153"}],"version-history":[{"count":0,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts\/2153\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/media\/2154"}],"wp:attachment":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/media?parent=2153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/categories?post=2153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/tags?post=2153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}